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Abstract
Background
This is an update of the Cochrane Review first published in 2010; it includes one
additional study.
Primary generalised tonic-clonic seizures are a type of generalised seizure. Other
types of seizures include: absence, myoclonic, and atonic seizures. Effective control
of tonic-clonic seizures reduces the risk of injury and death, and improves quality of
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life. While most people achieve seizure control with one antiepileptic drug, around
30% do not, and require a combination of antiepileptic drugs.
Objectives
To assess the effectiveness and tolerability of add-on lamotrigine for drug-resistant
primary generalised tonic-clonic seizures.
Search methods
For the latest update, we searched these databases on 19 March 2019: Cochrane
Register of Studies (CRS) Web, MEDLINE Ovid, and the WHO International Clinical
Trials Registry Platform (ICTRP). The CRS includes records from the Cochrane
Epilepsy Group Specialized Register, CENTRAL, Embase, and ClinicalTrials.gov.
We imposed no language restrictions. We also contacted GlaxoSmithKline,
manufacturers of lamotrigine.
Selection criteria
Randomised controlled parallel or cross-over trials of add-on lamotrigine for people
of any age with drug-resistant primary generalised tonic-clonic seizures.
Data collection and analysis
We followed standard Cochrane methodology; two review authors independently
assessed trials for inclusion, evaluated risk of bias, extracted relevant data, and
GRADE-assessed evidence. We investigated these outcomes: (1) 50% or greater
reduction in primary generalised tonic-clonic seizure frequency; (2) seizure freedom;
(3) treatment withdrawal; (4) adverse effects; (5) cognitive effects; and (6) quality of
life. We used an intention-to-treat (ITT) population for all analyses, and presented
results as risk ratios (RRs) with 95% confidence intervals (CIs); for adverse effects,
we used 99% CIs to compensate for multiple hypothesis testing.
Main results
We included three studies (total 300 participants): two parallel-group studies and one
cross-over study. We assessed varied risks of bias across studies; most limitations
arose from the poor reporting of methodological details. We meta-analysed data
extracted from the two parallel-group studies, and conducted a narrative synthesis
for data from the cross-over study.
Both parallel-group studies (270 participants) reported all dichotomous outcomes.
Participants taking lamotrigine were almost twice as likely to attain a 50% or greater
reduction in primary generalised tonic-clonic seizure frequency than those taking a
placebo (RR 1.88, 95% CI 1.43 to 2.45; low-certainty evidence). The results between
groups were inconclusive for the likelihood of seizure freedom (RR 1.55, 95% CI
0.89 to 2.72; very low-certainty evidence); treatment withdrawal (RR 1.20, 95% CI
0.72 to 1.99; very low-certainty evidence); and individual adverse effects: ataxia (RR
3.05, 99% CI 0.05 to 199.36); dizziness (RR 0.91, 99% CI 0.29 to 2.86; very low-
certainty evidence); fatigue (RR 1.02, 99% CI 0.13 to 8.14; very low-certainty
evidence); nausea (RR 1.60, 99% CI 0.48 to 5.32; very low-certainty evidence); and
somnolence (RR 3.73, 99% CI 0.36 to 38.90; low-certainty evidence).
The cross-over trial (26 participants) reported that 7/14 participants with generalised
tonic-clonic seizures experienced a 50% or greater reduction in seizure frequency
with add-on lamotrigine compared to placebo. The authors reported four treatment
withdrawals, but did not specify during which treatment allocation they occurred.
Rash (seven lamotrigine participants; zero placebo participants) and fatigue (five
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lamotrigine participants; zero placebo participants) were the most frequently reported
adverse effects.
None of the included studies measured cognition. One parallel-group study (N = 153)
evaluated quality of life. They reported inconclusive results for the overall quality of
life score between groups (P = 0.74).
Authors' conclusions
This review provides insufficient information to inform clinical practice.
Low-certainty evidence suggests that lamotrigine reduces the rate of generalised
tonic-clonic seizures by 50% or more. Very low-certainty evidence found inconclusive
results between groups for all other outcomes. Therefore, we are uncertain to very
uncertain that the results reported are accurate, and suggest that the true effect
could be grossly different.
More trials, recruiting larger populations, over longer periods, are necessary to
determine lamotrigine's clinical use.
Plain language summary
Lamotrigine as add-on therapy for
drug-resistant generalised tonic-clonic
seizures
This is an update of a review first published in 2010.
Background
Epilepsy is a common neurological (brain) condition that is characterised by
repeated seizures. Most people can control their seizures with a single antiepileptic
medicine, however, about 30% continue to have seizures. These people are said to
have drug-resistant epilepsy. Lamotrigine is an antiepileptic medicine, which can be
used as add-on treatment with other antiepileptic medication to try to manage drug-
resistant epilepsy.
Aim of review
This review studied whether lamotrigine was effective and tolerable when used as
add-on treatment, alongside other antiepileptic medicines, for people with drug-
resistant generalised epilepsy (affecting the entire brain from onset) with tonic clonic-
seizures (seizures where people lose consciousness and jerk quickly and
rhythmically).
Results
We found three trials, involving 300 people, that investigated lamotrigine for people
with drug-resistant generalised tonic-clonic seizures. People who received add-on
lamotrigine were almost twice as likely to have a 50% or greater reduction in the
number of generalised tonic-clonic seizures than people who received add-on
placebo (an inactive, dummy drug). Lamotrigine did not significantly affect: the
number of people who were completely free of seizures, the number of people who
withdrew from treatment, or the number of people who experienced common
adverse effects.
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However, we are very uncertain whether these findings are accurate. This is
because there were not many people involved in the studies, and we are unclear
about the methods some of the studies used. For this reason, we cannot comment
on the use of lamotrigine.
More trials, which include more people, and are carried out over longer time periods
are needed to properly guide the use of lamotrigine for people with drug-resistant
generalised tonic-clonic seizures.
The evidence is current to March 2019.
Summary of findings
Summary of findings 1
Add-on lamotrigine compared to placebo for drug-resistant generalised
tonic-clonic seizures
Add-on lamotrigine compared to placebo for drug-resistant generalised tonic-clonic seizures
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
7/3/2020 Cochrane Epilepsy Group: Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3DF0D9D28182E26AA201B64DEBE86C… 6/39
GRADE Working Group grades of evidence
High certainty. We are very confident that the true effect lies close to that of the estimate of the
effect.
Moderate certainty. We are moderately confident in the effect estimate; the true effect is likely to be
close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty. Our confidence in the effect estimate is limited; the true effect may be substantially
different from the estimate of the effect.
Very low certainty. We have very little confidence in the effect estimate; the true effect is likely to be
substantially different from the estimate of effect.
a Evidence downgraded once for risk of bias. The two studies included in the meta-analysis failed to
clarify whether outcome assessors were blinded. One study also failed to declare the treatment
allocation of all randomised participants who withdrew from treatment. Therefore, we awarded unclear
risk of bias.
b Evidence downgraded once for imprecision. The number of events did not satisfy the optimal
information size (< 400 events).
c Evidence downgraded twice for imprecision. The number of events did not satisfy the optimal
information size (< 100 events).
Background
This is an update of a Cochrane Review first published in 2010 (Tjia-Leong 2010); it
includes one additional study.
Epilepsy is defined as the occurrence of repeated epileptic seizures. It is a common
neurological disorder, with an estimated cumulative incidence of 68 per 100,000
people per year (Fiest 2017), and a worldwide prevalence of four to 10 per 1000
people (WHO 2019). Although the majority of people with epilepsy are able to
achieve control of their seizures by using adequate doses of conventional
antiepileptic drugs (AEDs), up to 30% of people develop drug-resistant epilepsy (i.e.
drug resistance), and continue to have seizures (Cockerell 1995). The internationally
accepted definition of drug-resistant epilepsy is the failure to respond to adequate
trials of two tolerated, appropriately chosen, and compliantly used antiepileptic drug
regimens, given with the intention of achieving complete cessation of seizures. The
two antiepileptic drugs can be used independently, or in combination (Kwan 2010).
For the purposes of this review, we applied this definition when assessing the
eligibility of studies for inclusion.
Description of the condition
Around 30% to 40% of people have seizures that are generalised at onset; most of
them are thought to have a genetic predisposition, and have primary generalised
(idiopathic) epilepsy (Bancaud 1989). Generalised seizures are those in which the
first clinical and electroencephalographic changes indicate that large parts of both
hemispheres of the brain are involved at the onset of the seizure. There is nearly
always impaired consciousness. The common subtypes of generalised seizures are
tonic-clonic seizures (grand mal), absence seizures (petit mal), and myoclonic
seizures. Such seizures tend to present in childhood and adolescence; common
syndromes include childhood absence, juvenile absence, juvenile myoclonic, and
generalised epilepsy with tonic-clonic seizures on waking. Around 20% to 30% of
people with generalised onset seizures fail to achieve seizure control on
monotherapy, and often require a combination of drugs to maximise seizure control
(Cockerell 1995).
Description of the intervention
In an attempt to achieve seizure control, clinicians often prescribe multiple AEDs.
Lamotrigine, the focus of this review, is an antiepileptic drug that can be used as an
add-on for people with drug-resistant epilepsy. It was initially licensed for people with
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drug-resistant focal epilepsy, with few studies examining its effect in people with
drug-resistant generalised seizures. In the UK, it has been licensed for generalised
tonic-clonic seizures as monotherapy and as add-on therapy. Numerous short-term,
randomised, double-blinded, placebo-controlled studies, predominantly of cross-over
designs, have confirmed the efficacy of lamotrigine, when used as add-on therapy for
people with drug-resistant, focal epilepsy (Ramaratnam 2016).
How the intervention might work
Lamotrigine acts by blocking voltage-gated sodium channels to stabilise the pre-
synaptic neuronal membrane (Leach 1995). There is some evidence that lamotrigine
also selectively inhibits the production of excitatory neurotransmitters, such as
glutamate and aspartate (Deng 2013). Its full mechanism of action remains unknown.
Although serum concentrations of lamotrigine are not thought to be influenced by
interactions with most drugs, they are affected by interactions with other anti-epileptic
drugs. Specifically, drug levels of lamotrigine are markedly increased by an
interaction with valproate, which inhibits glucuronidation, the main metabolic pathway
of lamotrigine (Rowland 2006; Weintraub 2005). Levels are decreased in the
presence of enzyme-inducing drugs, such as phenytoin, carbamazepine, and
oxcarbazepine (Weintraub 2005). A pharmacodynamic interaction is common when
lamotrigine is co-prescribed with carbamazepine, and the symptoms of neurotoxicity
(i.e. headache, nausea, dizziness, diplopia, and ataxia) can be avoided by reducing
the dose of carbamazepine (Besag 1998).
Adverse effects of lamotrigine include skin rash, dizziness, nausea, diplopia, and
ataxia. Increased toxicity and paradoxic deterioration of seizure control may occur
when lamotrigine is used in combination with other AEDs.
Why it is important to do this review
Lamotrigine may be efficacious as an add-on for generalised tonic-clonic seizures
(Beran 1998). However, compared with focal epilepsies, evidence for the
effectiveness of lamotrigine for people with generalised epilepsy syndromes is limited
(Marson 2007). This review evaluated whether the currently available literature can
adequately determine the efficacy of lamotrigine in people with primary generalised
epilepsy. This review does not address the effects of lamotrigine for Lennox-Gastaut
syndrome or for absence seizures, as both have already been discussed elsewhere
(Hancock 2013; Brigo 2019).
Objectives
To assess the effectiveness and tolerability of add-on lamotrigine for drug-resistant
primary generalised tonic-clonic seizures.
Methods
Criteria for considering studies for this review
Types of studies
We only included trials that met all of the following criteria:
1. randomised and controlled, with an adequate method of concealment of
randomisation;
2. double-blind, single-blind, or unblinded;
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3. placebo- or actively-controlled;
4. parallel-group or cross-over design.
Types of participants
Participants of any age, with drug-resistant, primary generalised epilepsy (i.e.
experiencing myoclonic epilepsy, generalised epilepsy with tonic-clonic seizures on
awakening, and other idiopathic seizures). We excluded studies involving
participants with absence epilepsy and Lennox Gastaut syndrome.
Types of interventions
1. The active treatment group received treatment with lamotrigine in addition to
their conventional antiepileptic drug (AED) treatment.
2. The control group received a matched placebo or an active comparator, such
as an alternative AED, in addition to their conventional AED treatment.
Types of outcome measures
Primary outcomes
1. 50% or greater reduction in primary generalised tonic-clonic seizure
frequency: the proportion of individuals with a 50% or greater reduction in
seizure frequency during the treatment period compared to the pre-
randomizations baseline period. We chose this because it is commonly
reported in this type of study, and can be calculated for studies that do not
report this outcome, provided that baseline seizure data were recorded.
Secondary outcomes
1. Seizure freedom: the proportion of individuals with a 100% reduction in
primary generalised tonic-clonic seizure frequency (complete cessation
seizures) during the treatment period (including maintenance phase) compared
to the pre-randomizations baseline period.
2. Treatment withdrawal. We used the proportion of individuals having treatment
withdrawn during the course of a treatment period as a measure of global
effectiveness. Treatment is likely to be withdrawn due to adverse effects, lack
of efficacy, or a combination. However, in trials of a relatively short duration,
adverse effects are likely to be the main reason for treatment withdrawal.
3. Adverse effects:
a. The proportion of individuals experiencing any of the following five
adverse effects (we chose these adverse effects because we considered






b. The proportion of individuals experiencing the five most common adverse
effects, if different from those listed above.
4. Cognitive effects. At present, there is no consensus as to which instrument
should be used to assess the effects of AEDs on cognition. In view of this
difficulty, we planned to tabulate results where a specific instrument was used
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to assess the effects of lamotrigine on cognition, but we did not combine the
results in a meta-analysis.
5. Quality of life. There is no consensus on which instruments should be used to
assess quality of life, so we tabulated the results rather than combine them in a
meta-analysis.
Search methods for identification of studies
Electronic searches
We ran searches for the original review in June 2010. We ran subsequent searches
in July 2012, October 2013, February 2014, February 2017, and March 2019. For the
latest update, we searched the following databases on 19 March 2019:
1. Cochrane Register of Studies Web (CRS Web), using the search strategy
shown in Appendix 1;
2. Medline Ovid (1946 to 19 March 2019), using the search strategy shown in
Appendix 2;
3. WHO International Clinical Trials Registry Platform (ICTRP), using the search
strategy shown in Appendix 3.
The Cochrane Register of Studies includes the Cochrane Epilepsy Group
Specialized Register, the Cochrane Central Register of Controlled Trials
(CENTRAL), and randomised or quasi-randomised, controlled trials from Embase,
and ClinicalTrials.gov.
Searching other resources
In addition, we contacted the manufacturers of lamotrigine, and checked any cross-
references from identified publications.
Data collection and analysis
Selection of studies
Two review authors (RB and MP) independently assessed the records identified by
both the electronic searches and handsearches for their eligibility for this review.
First, we (the two review authors), screened the titles and abstracts of all the
identified records. At this stage, we eliminated any records that were duplicates, or
that did not meet the predefined inclusion criteria. We retrieved the full-text
publications for the remaining, potentially eligible records, and completed a more in-
depth screening. We resolved any disagreements by discussion. If disagreements
persisted, the third author (AGM) arbitrated.
Data extraction and management
We extracted the following data from the studies that met our inclusion criteria:
1. Methodological or trial design:
a. method of randomizations and allocation concealment;
b. method of blinding;
c. whether any participants had been excluded from reported analyses;
d. duration of baseline period;
e. duration of treatment period;
f. dose(s) of lamotrigine tested.
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2. Participant and demographic information:
a. total number of participants allocated to each treatment group;
b. age and sex;
c. seizure types;
d. number and description of background drugs;
e. number of seizures prior to randomisation.
3. Treatment data:
a. medication dose per treatment group;
b. route of administration for treatment.
4. Follow-up data:
a. the number of participants in each group achieving 50% or greater
reduction in seizures;
b. the number of participants in each group achieving total cessation of
seizures;
c. the number of participants in each group who had treatment withdrawn,
and reasons for treatment withdrawal;
d. for those excluded; the reason for exclusion, whether any of those
excluded completed the treatment phase.
Assessment of risk of bias in included studies
Two review authors (RB and MP) independently assessed the risk of bias associated
with the included studies, using the Cochrane 'Risk of bias' tool, as outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The
Cochrane 'Risk of bias' tool comprises seven specific domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessors;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
For each entry, the two review authors made a judgement (low risk of bias, high risk
of bias, or unclear risk of bias) and provided support for the decision by an agreed
review author comment, or by a quote taken directly from the corresponding trial
publication.
When judging overall risk of bias associated with each study, we followed the
guidance suggested by Higgins 2017. Specifically, if a study was awarded low risk of
bias across all domains, we considered the study to be at low risk of bias overall. If
we judged that a study was at unclear risk of bias for one or more domains, then we
would award it unclear risk of bias overall. Likewise, if we judged that a study was at
high risk of bias for one or more domain, then we would consider the study to be at
high risk of overall bias.
Measures of treatment effect
We recorded the number of participants per randomised group who experienced
each outcome. We analysed data according to the intention-to-treat principle,
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whereby we assumed that participants who did not complete follow-up, or who
provided insufficient seizure data, were non-responders. To analyse dichotomous
outcomes (50% or greater reduction in seizure frequency, seizure freedom, treatment
withdrawal, and adverse effects), we calculated risk ratios (RRs) with 95%
confidence intervals (CIs), using the Mantel–Haenszel method. However, for
individual adverse effects, we quoted 99% CIs, to make allowance for multiple
testing.
Due to the lack of agreement and consistency about how cognitive effects and
quality of life should be measured, we tabulated any available results and conducted
a narrative synthesis.
Unit of analysis issues
For cross-over studies, we had planned to extract data from the first treatment
period, and incorporate the data into the meta-analysis, as if the data had been
derived from a parallel-group design study. This would prevent data gathered from
the same participant from contributing to both the intervention and control treatment
groups, thus avoiding any unit of analysis issues.
Dealing with missing data
Where outcomes of interest were not reported, we contacted the original authors and
study sponsors for further information.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the characteristics of the
participants recruited into the included studies, including factors, such as age and
sex. We assessed methodological heterogeneity by comparing the study design of
the individual studies, including: method of randomisation, allocation concealment
and blinding, and duration of treatment. We assessed statistical heterogeneity using
the I² statistic. An I² value < 40% suggested that heterogeneity might not be
important, 40% to 60% equated moderate heterogeneity, and 50% to 90% implied
substantial heterogeneity.
Assessment of reporting biases
We requested trial protocols to determine the predefined outcomes of the studies. In
instances where we were unable to get the trial protocol, we compared the outcomes
listed in the methods section to those reported in the results section of the text. We
reported any inconsistencies in the 'Risk of bias' table.
Due to the limited number of included studies, we were unable to develop a funnel
plot to evaluate reporting bias.
Data synthesis
We analysed all data using Review Manager 5 (Review Manager 2014). Where the I²
statistic indicated that heterogeneity was likely unimportant (I² < 40%), we
summarised results using a fixed-effect model. When the I² statistic indicated either
moderate or substantial heterogeneity (I² ≥ 40%), or we detected clinical
heterogeneity despite insignificant statistical heterogeneity, we used a random-
effects model for the meta-analysis.
Subgroup analysis and investigation of heterogeneity
Due to the small number of included studies, we were unable to conduct any
meaningful subgroup analysis. If it had been possible, we would have undertaken a
subgroup analysis according to age groups (children versus adults), seizure type,
and baseline severity.
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Sensitivity analysis
We had also planned to complete a sensitivity analysis to test the robustness of the
meta-analysis. Specifically, we would have excluded studies from the meta-analysis
that were at high-risk of bias, to determine the impact on the overall effect size
estimated.
Summary of findings and assessment of the certainty of the
evidence
We used the GRADE approach to summarise findings, as detailed in the GRADE
handbook (Schünemann 2013). We imported data into GRADEpro GDT software
from Review Manager 5 software to create a 'Summary of findings' table (GRADEpro
GDT; Review Manager 2014). We assessed the certainty of the evidence for the
following outcomes in the 'Summary of findings' table: 50% or greater reduction in
seizure frequency, seizure freedom, treatment withdrawal, and the adverse effects of
dizziness, fatigue, nausea, and somnolence.
We chose to include 50% or greater reduction in seizure frequency and seizure
freedom as these were the only two efficacy outcomes included in the review. We
also chose to include treatment withdrawal as this is a measure of global
effectiveness that encompasses both efficacy and tolerability. Finally, we wanted to
include all five adverse effects that are considered to be important and common with
AEDs (ataxia, dizziness, fatigue, nausea and somnolence). However, because we
were limited by the number of outcomes that can be GRADE-assessed and included
in the summary of findings table, we decided to exclude ataxia as our previous
knowledge of the evidence base suggested that ataxia would not be highly reported.
We therefore prioritised the GRADE-assessment of the other four adverse effects.
Results
Description of studies
Results of the search
During the original search, conducted in June 2010, we identified five randomised
controlled studies investigating the use of add-on lamotrigine in participants with
drug-resistant generalised epilepsy (Beran 1998; Biton 2005; Eriksson 1998; Motte
1997; Sander 1990). Of the studies identified during the original searches, only two
of the studies fulfilled the protocol criteria for inclusion, one cross-over and one
parallel study (Beran 1998; Biton 2005).
The electronic searches conducted between July 2012 and March 2019, identified a
total of 454 records that were potentially eligible for inclusion (Figure 1). We also
identified five records through handsearching. We automatically removed 115
records, as they were duplicates. Next, we removed another 240 records, because
they were obviously irrelevant. We screened the titles and abstracts of the remaining
104 records, and determined that only eight of the identified records, which related to
four individual studies, were potentially eligible for inclusion. We retrieved and
screened the full-text publications of the remaining eight records, five of which we
found to be eligible for inclusion. Four related to Biton 2010, and two were additional
references for Biton 2005. We excluded two of the full-texts (Brzakovic 2012; Chung
2009).
In total, we assessed that 10 records, relating to three individual studies, were
eligible (Beran 1998; Biton 2005; Biton 2010). We excluded five records, relating to
five individual studies (Brzakovic 2012; Chung 2009; Eriksson 1998; Motte 1997;
Sander 1990).
7/3/2020 Cochrane Epilepsy Group: Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3DF0D9D28182E26AA201B64DEBE86… 13/39
Included studies
We included three studies in this update (Beran 1998; Biton 2005; Biton 2010). We
summarised the relevant information for each study in the 'Characteristics of
included studies' tables.
Study design
One study was a cross-over study (Beran 1998) whilst two studies were parallel-
group studies (Biton 2005; Biton 2010).
The cross-over study (Beran 1998) featured an eight week baseline period, followed
by two eight week treatment periods, separated by a four week washout period. No
detailed data were provided for either phase of the cross-over study.
The parallel-group studies (Biton 2005; Biton 2010) both used the same study
duration for adolescent and adult participants; a two-week screening period, an
eight-week baseline period, and a 19-week treatment period (7-week dose-
escalation plus a 12-week maintenance period). Biton 2005, however, also included
children (aged 2 to 12 years) and for these participants the dose-escalation was 12-
weeks, leading to an overall treatment period of 24-weeks, opposed to 19-weeks for
adults. All other phases remained the same in duration.
Participants
Beran 1998 included a small sample of 26 participants, aged between 15 and 50
years (mean 29 years), with drug-resistant generalised epilepsy. Of the 26
participants, 17 participants had generalised epilepsy with tonic-clonic seizures (12
with tonic-clonic and absence seizures, two with tonic-clonic seizures only, one with
tonic-clonic and myoclonic seizures, two with tonic-clonic, absence and myoclonic
seizures). Only the 17 participants with tonic-clonic seizures were included in our
intention-to-treat analysis.
SImilar to Beran 1998, Biton 2010 included both adolescents and adults, but not
children. Specifically, Biton 2010 involved 153 randomised participants (76
lamotrigine, 77 placebo), aged 13 years and over. In contrast, Biton 2005 included
children, as well as adults and adolescents. Biton 2005 included 121 randomised
subjects, aged 2 to 55 years (mean 26 years).
Notably, four of the participants from Biton 2005 did not receive any study medication
and it was not clear to which group they had been randomised. As a result, we were
only able to include 117 participants (58 lamotrigine, 59 placebo) in our intention-to-
treat analysis includes.
For both Biton 2005 and Biton 2010, participants had been receiving 1 or 2
established AEDs for at least four weeks prior to screening. In contrast, Beran 1998
included participant who had previously been treated with up to four established
antiepileptic drugs (AEDs). For all three studies, participants had to have drug-
resistant seizures despite therapy with a stable AED regimen of at least one or more
other AEDs, appropriate for the type of epilepsy when given in adequate doses.
The exclusion criteria for all three studies were similar. They excluded people with: a
history of focal seizures, interictal expression of focal seizures revealed by EEG,
Lennox-Gastaut syndrome, confounding organic or psychiatric problems, progressive
neurological disease, associated systemic disease, chronic medication that might
influence seizure control, recent use of any investigational AED, previous exposure
to lamotrigine, and abuse of alcohol, other prescription or non-prescription drugs.
Furthermore, the three studies each excluded women who were pregnant or at risk
of pregnancy, and women who were breastfeeding.
Interventions
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Participants were not randomised to a single dose in any of the studies but took a
range of doses, depending on clinical response, age group, and the concurrent
administration of other antiepileptic drugs (AEDs).
Valproate was the most common concomitant AED. Lamotrigine was administered at
lower doses when used with an enzyme inhibitor like valproate (75 mg to 250 mg
daily). Conversely, higher doses were administered when used with other enzyme
inducing AEDs (150 mg to 500 mg daily). Additionally, for Biton 2010, participants
who were taking an AED other than valproate and taking multiple enzyme-inducing
AEDs were titrated to 300 mg/day. Conversely, participants under the age of 12
years (N = 23) had a dosing range between 2.25 mg and 7.5 mg/kg/day (Biton
2005).
Excluded studies
We excluded five studies from this review update (Brzakovic 2012; Chung 2009;
Eriksson 1998; Motte 1997; Sander 1990). We summarised the reasons for
exclusion in the 'Characteristics of excluded studies' tables.
Four of the studies featured ineligible study populations (Chung 2009; Eriksson
1998; Motte 1997; Sander 1990). Two studies included participants with a diagnosis
of Lennox-Gastaut syndrome (Eriksson 1998; Motte 1997); one study included
participants with a diagnosis of focal, rather than generalised epilepsy (Chung 2009);
the majority of participants in one study had drug-resistant focal seizures, and
although three of the participants did have primary generalised tonic-clonic seizures,
data were not stratified according to seizure subtype or order of treatment (Sander
1990). One study was not a randomised controlled trial (Brzakovic 2012).
Risk of bias in included studies
Summaries of our judgements for each risk of bias domain, across the included
studies, are presented in Figure 2 and Figure 3. Reasons supporting our
judgements, including quotations taken directly from the text publications and
specific review author comments, can be found in the 'Risk of bias' tables.
Allocation
One study failed to explicitly state how the randomisation sequence was generated
or how allocation was concealed, therefore, we assessed it as an unclear risk of bias
(Beran 1998). The other two studies specified that the randomisation schedule was
computer-generated by the study sponsor, GlaxioSmithKline; they used central
randomisation and an interactive voice response system to allocate participants to
treatment groups, therefore, we assessed them at a low risk of bias.
Blinding
All three studies reported they were double-blinded. However, one study did not
provide a description of the blinding process, and we assessed it as unclear risk of
performance and detection bias (Beran 1998). The other two studies specified that
matching placebo tablets were used, consequently, we judged them at low risk of
performance bias. Since they did not specify whether outcome assessors were
blinded, we assessed that the studies were at unclear risk of detection bias.
Incomplete outcome data
All three studies reported losses to follow-up and treatment withdrawals.
Beran 1998 reported that 4/26 participants withdrew from the trial before completion,
but did not specify which treatment group the participants were randomised to at the
time of withdrawal, as a result, we judged the study at high risk of attrition bias.
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Biton 2005 reported that 16/58 lamotrigine-randomised participants and 14/59
placebo-randomised participants withdrew from the trial prior to completion. Data
from the 30 participants who withdrew from treatment, but who all received at least
one dose of the study drug, were incorporated into the efficacy analysis by using an
intention-to-treat analysis. An additional 4/117 participants did not receive at least
one dose of the study drug, but their treatment group was not specified, so were not
included in the meta-analysis; for this reason, we assessed that the study was at
unclear risk of attrition bias.
Biton 2010 reported that 10/76 lamotrigine-randomised participants and 8/77
placebo-randomised participants withdrew from the study prior to completion, but
they used an intent-to-treat analysis. Therefore, we assessed the study had a low
risk of attrition bias.
Selective reporting
We were unable to attain a trial protocol for one study, but the outcomes defined in
the methods section of the full-text publication were fully reported in the results
section. We obtained the summary of the trial protocol for the remaining two studies,
which fully reported all predefined outcomes. Therefore, we assessed all three
studies at low risk of reporting bias.
Other potential sources of bias
Beran 1998 experienced difficulties when recording participants' daily seizure
frequency. Specifically, 22 of the randomised participants experienced absence
seizures. This seizure type can be difficult to accurately record. The authors,
therefore, only collected seizure frequency data on days when they were sure that a
complete and accurate seizure record had been kept. The mean monthly seizure
rate was then calculated based from the number of days were a complete seizure
record was available. It is thus possible that the mean monthly seizure frequency
calculated could be considerably different from the true monthly seizure frequency.
This would be especially problematic if the number of generalised tonic-clonic
seizures correlated with the number of absence seizures, in any way. We thus
assessed that the study by Beran 1998 was at unclear risk of other bias.
Effects of interventions
We did not conduct a meta-analysis in the previous version of this review as we
included two studies that were too heterogeneous. Specifically, the two studies
varied in: study design (one study was a parallel-group trial (Biton 2005) whereas the
other was a cross-over trial (Beran 1998)), treatment doses used (200 mg to 400
mg/day versus 75 mg to 150 mg/day), and length of follow-up (19 weeks to 24 weeks
versus 8 weeks).
During this review update, we identified a second parallel group study (Biton 2010)
with the same duration of treatment as the previously included parallel-group study
(Biton 2005). We therefore decided to conduct a meta-analysis of the two parallel-
group studies, whilst continuing to describe the results from the cross-over study
narratively (Beran 1998). Importantly, the narrative synthesis considers data
collected from the same participant for both the intervention (lamotrigine) and control
(placebo) treatment periods, due to the cross-over design of the study. Unfortunately.
the information regarding only the first treatment period was not available.
The results can be found summarised in the Summary of findings table 1.
Primary outcome
50% or greater reduction in primary generalised tonic-clonic seizure frequency
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All three studies reported this outcome, however, we only used data extracted from
the two parallel-group studies for the meta-analysis (Biton 2005; Biton 2010). We
calculated that participants receiving add-on lamotrigine were nearly twice as likely to
attain a 50% or greater reduction in primary generalised tonic-clonic seizure
frequency, compared to participants who received add-on placebo (risk ratio (RR)
1.88, 95% confidence interval (CI) 1.43 to 2.45; P < 0.001; 2 studies; 270
participants; Analysis 1.1).
Beran 1998 (N = 17) reported that seven participants with tonic-clonic seizures
experienced a 50% or greater reduction in primary generalised tonic-clonic seizure
frequency with add-on lamotrigine compared to with add-on placebo. Importantly,
seizure frequency was compared between the two treatment arms to calculate the
percentage change rather than to the pre-randomisation baseline period. Analysis
using the non-parametric Mann Whitney U test revealed a significant reduction in
seizure frequency with add-on lamotrigine compared with add-on placebo (P = 0.03).
Only one participant experienced an increase in seizure frequency when receiving
add-on lamotrigine compared to when receiving add-on placebo.
Secondary outcomes
1. Seizure freedom
The two parallel-group studies (Biton 2005; Biton 2010), presented data for the
outcome, seizure freedom, however, the cross-over study by Beran 1998 did not.
We calculated that a greater proportion of participants attained seizure freedom from
primary generalised tonic-clonic seizures when receiving add-on lamotrigine
compared to when receiving add-on placebo. The meta-analysis (Analysis 1.2),
however, indicated that the results were inconclusive and we were unable to
determine whether there was an effect of vigabatrin for seizure freedom (RR 1.55,
95% CI 0.89 to 2.72; P = 0.12; 2 studies; 270 participants).
2. Treatment withdrawal
All three studies measured treatment withdrawal. For the parallel group studies, the
results were inconclusive (RR 1.20, 95% CI 0.72 to 1.99; P = 0.48; 2 studies; 270
participants; Analysis 1.3). For participants randomised to placebo, the most
common reason for treatment withdrawal was non-compliance (total 10/22
withdrawals). For participants randomised to lamotrigine groups, the most common
reason for treatment withdrawal varied between the two studies. Non-compliance
remained the most common reason for treatment withdrawal in Biton 2010 (7/10
withdrawals); whereas loss to follow-up and adverse effects were the most common
reasons in Biton 2005 (5/16 withdrawals). Other reasons for treatment withdrawal for
both treatment groups included withdrawal of consent and lack of efficacy.
Beran 1998 reported that four of the total 26 randomised participants withdrew from
treatment. Two participants withdrew from the lamotrigine group due to rash, one
participant withdrew during the first treatment phase, and the other participant was
later found to be ineligible. There was no information on treatment group for the latter
two treatment withdrawals and we do not know the seizure type of the four
participants who withdrew.
3. Adverse effects
a. The proportion of individuals experiencing any of the following five listed adverse effects
Both parallel-group studies reported all five adverse effects. The results were
inconclusive for all adverse effects (2 studies, 270 participants; Analysis 1.4):
1. Ataxia – RR 3.05, 99% CI 0.05 to 199.36; P = 0.49;
2. Dizziness – RR 0.91, 99% CI 0.29 to 2.86; P = 0.84;
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3. Fatigue – RR 1.02, 99% CI 0.13 to 8.14; P = 0.99;
4. Nausea – RR 1.60, 99% CI 0.48 to 5.32; P = 0.32;
5. Somnolence – RR 3.73, 99% CI 0.36 to 38.90; P = 0.15.
Beran 1998 reported that 3/26 (12%) of the participants experienced ataxia, 2/26
(8%) experienced dizziness, and 2/26 (8%) experienced somnolence, whilst
receiving lamotrigine. None of the participants in the placebo group reported any of
these symptoms. The report described tiredness rather than fatigue; 1/26 (4%)
participants reporting tiredness in the lamotrigine group, 5/26 (19%) reported it in the
placebo group. Of significance, the report only listed adverse effects that were
reported by more than two participants. Although nausea was not listed amongst the
adverse effects, it is possible that two or fewer participants reported it.
b. The proportion of individuals experiencing the five most common adverse effects, if different
from those listed above
Both parallel studies reported headache as the most common adverse effect during
the studies; there were more reports of headache in the placebo group, but the
results were inconclusive (RR 0.75, 99% CI 0.38 to 1.50; P = 0.29; 2 studies, 270
participants; Analysis 1.4).
Biton 2010 reported that vomiting was the second most commonly reported adverse
effect, Biton 2005 reported it was the fifth most commonly reported; the results were
inconclusive (RR 1.27, 99% CI 0.39 to 4.15; P = 0.60; 2 studies, 270 participants;
Analysis 1.4).
Convulsion was the fourth most commonly reported adverse effect in Biton 2005;
while more common in the placebo group, the results were inconclusive (RR 0.34,
99% CI 0.05 to 2.13; P = 0.13; 2 studies, 270 participants; Analysis 1.4).
Pyrexia was the fifth most commonly reported adverse effect in Biton 2010; the
results were inconclusive (RR 0.87, 99% CI 0.21 to 3.52; P = 0.80; 2 studies, 270
participants; Analysis 1.4).
In addition to the adverse effects listed above, Beran 1998 also reported rash,
headache, accidental injury, ataxia, diplopia, and tremor in their top five reported
adverse effects. Rash was the most commonly reported adverse effect (lamotrigine =
7/26 (27%); placebo = none); headache and accidental injury were tied for the third
most common, with 2/26 reported in each group; ataxia, diplopia, and tremor were
tied for the fourth most common (lamotrigine = 3/26 (12%) reported ataxia and
diplopia; placebo = none; lamotrigine = 2/26 (8%) reported tremor; placebo = 1/26
(4%)).
4. Cognitive effects and quality of life
None of the three included studies assessed any measures of cognitive effect.
5. Quality of life
Only one study (N = 153 participants) assessed quality of life with the Quality of Life
in Epilepsy-31-P (QOLIE-31P) questionnaire. The mean overall quality of life score
for both treatment groups increased from baseline to the end of treatment, but the
results were inconclusive (P = 0.74; Table 1; Biton 2010).
Discussion
Summary of main results
We found three short-term randomised controlled trials that met our inclusion criteria,
two of which were parallel-group studies (Biton 2005; Biton 2010), and one of which
7/3/2020 Cochrane Epilepsy Group: Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3DF0D9D28182E26AA201B64DEBE86… 18/39
was a cross-over study (Beran 1998). We combined the results from the two parallel-
group studies in a meta-analysis, and described the results from the cross-over study
narratively.
Low-certainty evidence suggested that add-on lamotrigine almost doubled the
likelihood that people with generalised tonic-clonic seizures would attain a 50% or
greater reduction in the frequency of their seizures, compared to add-on placebo.
Very low-certainty evidence suggested inconclusive results for the likelihood of
seizure freedom between add-on lamotrigine and placebo. Very low-certainty
evidence suggested inconclusive results for the likelihood of adverse events, such as
treatment withdrawal and individual adverse effects.
Importantly, the low- to very low-certainty evidence for all outcomes means that we
are uncertain to very uncertain that the effect sizes that we reported are accurate. It
is possible that the true effect could be considerably different to that estimated, both
in terms of magnitude and direction. The uncertainty of the results may reflect the
very low number of studies and participants that contributed data to the meta-
analysis.
Overall completeness and applicability of evidence
The most notable limitation of this review is the lack of studies that were eligible for
inclusion. We included three studies, however, only data from two of the studies were
suitable for meta-analysis. Even after combining the two study populations, the total
sample size remained relatively small (270 participants in total). Less frequent
events, such as seizure freedom and the incidence of individual adverse effects,
require larger sample sizes to detect a significant therapeutic effect (Hajian-Tillaki
2011). From this viewpoint, it is possible that add-on lamotrigine might have a
therapeutic effect on these outcomes that we have currently been unable to detect.
The limited data also prevented us from performing subgroup analyses. We had
originally planned to conduct subgroup analyses according to the age of participants,
their seizure type, and their baseline seizure frequency. However, splitting the small
sample size further would have rendered the results of any subgroup analysis
meaningless, and increased the likelihood of a type II error occurring.
The studies did not report all of the review outcomes; for example, Beran 1998 did
not report seizure freedom, and none of the included studies reported any measures
of cognitive effect. Only Biton 2010 measured and reported changes in quality of life.
This also impacted the completeness and certainty of the evidence.
The design of the included studies also affected the applicability of the evidence. All
three included studies were of short duration; hence, longer term outcomes were not
assessed. Long-term outcomes are especially important in chronic conditions, such
as epilepsy, where the medications could potentially be taken over a lifetime.
All three studies tried to account for interactions between lamotrigine and enzyme-
inhibiting drugs (valproate) and enzyme-inducing drugs (e.g. carbamazepine) by
altering initial lamotrigine doses to compensate. Of note, the initial target doses were
different between the studies. For example, for participants taking add-on lamotrigine
with valproate, but without an enzyme-inducing drug, Beran 1998 administered a
fixed-dose of 150 mg/d lamotrigine. In contrast, the target dose for participants taking
concomitant valproate in Biton 2005 and Biton 2010 was 200 mg/d lamotrigine, the
minimum dose was 150 mg/d and the maximum was 250 mg/d. Again, this affected
our ability to combine and compare the results of the three studies.
Of further significance, the approach to dosing did not reflect how lamotrigine and
other antiepileptic drugs are used in practice. Beran 1998 used a fixed-dose
regimen, which does not reflect everyday practice; in normal clinical practice,
individuals would alter their dose, dependent on their tolerability of the drug and their
therapeutic response. In contrast, Biton 2005 titrated doses according to
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plasma levels of lamotrigine, which, again, is not routine clinical practice. Therefore,
it is unclear how easily the findings would transfer to clinical practice.
On a more positive note, the two studies that contributed data to the meta-analysis
did include a range of participants; for example, both adults and children were
involved in both studies. A mixture of ethnicities were also recruited into the studies,
most noticeably, Caucasian, Asian, and Hispanic populations. Due to our inability to
complete any subgroup analyses, we were unable to determine whether the findings
were generalisable to all participant demographics, or whether a participant's
response to lamotrigine was dependent upon certain personal characteristics.
Certainty of the evidence
Data from only two of the included studies contributed to the meta-analysis. Data
from Beran 1998 was excluded from the meta-analysis. The findings from Beran
1998 are instead described in the comments column of the Summary of findings
table 1.
With regard to risk of bias, one of the included trials failed to describe the
methodology used for random sequence generation, allocation concealment, and the
blinding of participants, study personnel, and outcome assessors (Beran 1998).
None of the studies provided details about whether outcome assessors were blinded.
There were also issues with the reporting and handling of attrition for two of the
included studies (Beran 1998; Biton 2005). Both studies failed to specify the
treatment allocation of a subset of participants who withdrew from treatment, and
one study did not conduct intention-to-treat analyses (Beran 1998). The same study
was also at risk of other bias due to the method used to calculate the baseline
seizure frequency. As a result, we downgraded the evidence once for risk of bias for
all seven outcomes, largely due to the concerns regarding the blinding of outcome
assessors and the issue with attrition.
We also downgraded the evidence for imprecision, owing to the insufficient number
of events contributing to the data analysis. Specifically, we downgraded the evidence
twice for six of the outcomes because fewer than 100 events were reported per
outcome. In contrast, we only downgraded the evidence for the primary outcome,
50% or greater reduction in seizure frequency, once, as more events were reported
for this outcome (131 events/270 participants for the meta-analysis).
Overall, we assessed that six of the outcomes were supported by very low-certainty
evidence, and one outcome was supported by low-certainty evidence. Therefore, we
are uncertain to very uncertain that the findings reported are accurate of the true
effect of add-on lamotrigine compared to placebo, and readers should be very
cautious about how they interpret and apply the results.
Potential biases in the review process
We conducted the review according to the standard methodological procedures
expected by the Cochrane Collaboration. We therefore have no reason to suspect
any major potential biases in this review.
Agreements and disagreements with other studies
or reviews
The most similar systematic review to the one conducted here was by Bloom 2017.
The review by Bloom 2017 investigated the occurrence of adverse effects with
lamotrigine monotherapy in randomised controlled trials. The authors identified 122
studies for inclusion, consisting of 18,698 participants. The incidence rate for rash
was 8.3%, with 1570 participants affected in total. Although the systematic review by
Bloom 2017 focused on the use of lamotrigine as a monotherapy, rather than as an
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add-on therapy, the evidence from the review suggests that the incidence of rash
should be higher than that which has been reported by our meta-analysis.
This could be due to the different dosing regimens implemented. For example, Beran
1998 used a fixed-dose method and did not describe any dose adjustments. In our
review, Beran 1998 reported that 27% of participants developed rash whilst receiving
add-on lamotrigine, of which, two cases were serious enough for treatment to be
withdrawn. No participants developed rash with add-on placebo. Biton 2005 and
Biton 2010, however, allowed flexibility within their target doses by permitting a range
of doses for each target dose. Participants were required to remain within the dose
range but were allowed to adjust their dosage, as necessary, dependent on
tolerability and efficacy. Biton 2005 reported one mild case of generalised urticaria
whilst Biton 2010 reported a higher incidence rate for rash among placebo-
randomised participants compared to lamotrigine-randomised participants (four
versus two participants, respectively). Although Bloom 2017 did not describe the
dosing regimes of the included studies, we suggest that this presents one possible
explanation for the difference in incidence rates.
Further to this, the systematic review by Bloom 2017 also addressed the occurrence
of Stevens-Johnson syndrome and toxic epidermal necrolysis. Both conditions are
classified as being severe adverse skin reactions and are considered under the
category of rash. Specifically, Bloom 2017 estimated that Stevens-Johnson
syndrome/ toxic epidermal necrolysis affects one in 2500 participants treated with
lamotrigine. Notably, none of the studies, included in our review, reported any
occurrence of Stevens-Johnson syndrome or toxic epidermal necrolysis. This is
easily explained by the low number of participants involved across all three studies
(300 participants total) and the rarity of the event.
Although neither skin reaction was reported within our review, due to the seriousness
and mortality associated with Stevens-Johnson syndrome/toxic epidermal necrolysis
(Kumar 2018), it is important that this eventuality is considered when debating the
clinical use of lamotrigine. Multiple studies have demonstrated that the risk of an
adverse skin reaction can be minimised by the slow, gradual up-titration of
lamotrigine dosage (Ketter 2005; Lorberg 2009). It is, however, worth noting that
people would not be effectively protected against seizures during the titration period.
Authors' conclusions
Implications for practice
At present, the evidence neither supports nor refutes the use of lamotrigine as an add-on
for drug-resistant generalised tonic-clonic seizures.
Low-certainty evidence suggested that add-on lamotrigine may be efficacious at producing
a 50% or greater reduction in primary generalised tonic-clonic seizure rate than add-on
placebo. Very low-certainty evidence provided inconclusive results as to whether add-on
lamotrigine affects seizure freedom rate or the incidence of adverse effects.
All outcomes in this review was rated as low to very low certainty meaning we are uncertain
to very uncertain that the effects reported are accurate. Consequently, it is likely that the
true effects of lamotrigine are significantly different from that reported in this review. We thus
lack confidence in our findings and urge readers to interpret the results with caution.
Implications for research
The results presented for lamotrigine's efficacy and tolerability in drug-resistant generalised
tonic-clonic seizures are based on limited evidence from randomised controlled trials. The
included trials varied widely in design and duration. The best studies are well-designed,
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randomised, blinded, long-term, prospective trials that evaluate the efficacy and tolerability
of a drug.
To more fully evaluate the role of lamotrigine, further studies are required. Such studies
should address the following:
1. The minimum and maximum effective doses of lamotrigine as add-on therapy in
generalised tonic-clonic seizures;
2. The long-term efficacy and safety of add-on lamotrigine in generalised onset tonic-
clonic seizures;
3. How lamotrigine compares with other add-on therapies in drug-resistant generalised
tonic-clonic seizures;
4. How lamotrigine interacts with standard antiepileptic drugs in people with generalised
onset tonic-clonic seizures (or idiopathic generalised epilepsy);
5. Determine if people with generalised epilepsy, who have drug-resistant seizures, are
physiologically or genetically different from those with readily controlled seizures;
6. Effects of lamotrigine on quality of life and cognition;
7. Economic aspects of lamotrigine therapy.
Future studies should:
1. explore multiple doses of lamotrigine and evaluate dose-response relationships;
2. introduce longer maintenance and follow-up periods;
3. incorporate active controls into their study design;
4. assess drug-interactions;
5. incorporate genetic and physiological investigations;
6. assess quality of life and cognition;
7. evaluate cost-effectiveness.
It is important to acknowledge that placebo-controlled trials in people with drug-resistant
generalised tonic-clonic seizures would now be considered unethical. This is because
lamotrigine is generally regarded to be beneficial, despite the findings of this current
systematic review. Hence, it is more likely that any future studies would be active-controlled
trials, using another antiepileptic drug as a comparator, rather than placebo-controlled.
A comparative study would still be capable of providing evidence for a therapeutic effect of
lamotrigine. Findings from multiple studies using active-comparators could then be used to
infer how lamotrigine would perform compared to a drug with which it has not yet been
actively compared. From this viewpoint, an active-controlled trial would help the
interpretation of comparative studies and could prove advantageous.
From an ethical perspective, an active-controlled trial could be of at least 12 months
duration because both treatment groups would receive an active treatment. Consequently,
there would be no ethical issues with regard to participants receiving a long-term inactive,
placebo treatment. Trials of longer duration could measure outcomes that include seizure
remissions, adverse effects with long-term exposure, and quality of life. All of these
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Differences between protocol and
review
We made several changes from the review protocol and the previous version of this
review during the current review update (Tija-Leong 2009; Tjia-Leong 2010).
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1. We changed all references to 'refractory' epilepsy to drug-resistant, in
accordance with new nomenclature (Kwan 2010).
2. We changed the definition of drug-resistant epilepsy from 'the failure to respond
to one or more appropriately used AEDs', as described in the 2010 version of
this review, to 'the failure to respond to adequate trials of two tolerated,
appropriately chosen, and compliantly used antiepileptic drug regimens, given
with the intention of achieving complete cessation of seizures'. We made this
change due to the introduction of an internationally-accepted definition by the
International League Against Epilepsy (ILAE (Kwan 2010)).
3. We have altered the objective of the review such that it remains consistent with
the objective stated in the protocol but now follows the format suggested by the
Cochrane guidelines.
4. We renamed the outcomes to ensure that our terminology was consistent with
other Cochrane Epilespy reviews. Importantly, we did not change the
definitions of any of the outcomes.
5. For this review update, we assessed the risk of bias, associated with the
included studies, using the Cochrane 'Risk of bias' tool (see Assessment of risk
of bias in included studies), rather than the Jadad validated quality scale
(Jadad 1996), as stated in the review protocol.
6. We changed the measure of treatment effect from relative risk, as specified in
the review protocol, to risk ratio. Relative risk is commonly misunderstood,
whereas risk ratio is easier to understand and does not lead to an exaggerated
sense of risk. This is an especially common issue when the event rate for the
control group is unknown.
7. We specified that we used the Mantel-Haenszel statistical method to calculate
the effect measure. We did not state this in either the protocol or the previous
version of the review.
8. We added methods for dealing with unit of analysis issues (see Unit of analysis
issues), as we did not address these in the review protocol or the previous
version of the review.
9. We have changed the range for I² value that would indicate moderate
heterogeneity from 30% to 60% (defined in protocol) to 40% to 60% to prevent
any uncertainty or subjectivity.
10. We specified the sensitivity analyses that would have been completed, if
possible, as it we had not previously described them in either the review
protocol or the previous version of the review.
11. We incorporated GRADE methodology to assess the certainty of the evidence
for each outcome in this update, and developed and incorporated a 'Summary
of findings' table. We did not include this in the previous version as it was not
yet mandatory.
Characteristics of studies




Methods Study design: multicentre, randomised, double-blind, cross-over study
Country: Australia
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Study duration:
1. 8-week prospective baseline;
2. 8-week period per treatment arm;
3. 4-week washout period, including 1-week taper.
Participants
Number of randomised participants: 26
Type of epilepsy or seizure: drug-resistant generalised epilepsy
Sex: 11 males and 15 females
Age (mean): 29 years (range 15 to 50)
Number of concomitant AEDs: up to 4 other AEDs permitted
Number of randomised participants with tonic-clonic seizures: 17
Number of participants with tonic-clonic seizures included in efficacy analysis:
14
Monthly tonic-clonic seizure frequency at baseline (mean (range)): 4.7 (1 to 24)
Interventions
Treatment arms: 1 placebo, 1 lamotrigine
Details: lamotrigine or placebo given as add-on therapy. All participants were taking
valproate. Daily lamotrigine regimes were 150 mg/day for participants taking valproate
and an enzyme-inducing AED versus 75 mg/day for participants taking valproate
without an enzyme. Both were taken as a once daily dose. There was no information
describing how placebo was administered.
Outcomes
1. 50% responder rate















































Quote: "Four patients withdrew before completion... These patients were
included in the safety analysis but excluded from the efficacy analysis."
Comment: the text reported the total number of treatment withdrawals
(attrition), however, the text did not specify which treatment the participants
were receiving when they withdrew. Furthermore, intent-to-treat analysis






Comment: we were unable to attain a trial protocol, however, all outcomes




Quote: "Some patients were unable to record seizure numbers at
occasional times during the trial, particularly those patients having frequent
7/3/2020 Cochrane Epilepsy Group: Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3DF0D9D28182E26AA201B64DEBE86… 26/39
absence seizures. For this reason, a seizure rate for each treatment period
was calculated based on the number of days, during each treatment
period, that a complete seizure record was available."
Comment: mean monthly seizure frequency was only calculated from the
days when a complete seizure record was available and could vary




Study design: single-centre, randomised, double-blind, parallel study
Country: USA
Study duration:
1. Up to 2-week screening phase;
2. 8-week pre-randomisation baseline;
3. 19-week treatment period for adolescents and adult participants (aged over 12
years: 7-week dose escalation plus 12-week maintenance phase) versus a 24-
week treatment period for paediatric participants (aged 2 to 12 years: 12-week
dose escalation plus 12-week maintenance phase);
4. Optional entry into one year open-label continuation phase (all participants to
receive lamotrigine).
Participants
Number of randomised participants: 121 (placebo 59 participants; lamotrigine 58
participants; 4 participants did not receive either study drug)
Number of participants included in efficacy analysis: 117
Type of epilepsy or seizure: primary generalised tonic-clonic seizures
Sex (number (%)): placebo 26/59 (50%) females; lamotrigine 29/58 (44%) females
Age (mean ± SD): placebo 24.9 ± 13.8 years; lamotrigine 26.9 ± 14.6 years; age
range from 2 to 55 years
Number of concomitant AEDs: up to 2 other AEDs permitted
Interventions
Treatment arms: 1 lamotrigine, 1 placebo;
Details: lamotrigine or placebo given as add-on therapy. Lamotrigine schedule was
based on age and concomitant AEDs:
Participants aged 2 to 12 years: (i) taking concomitant valproate: 3 mg/kg/day target
dose (200 mg/d maximum dose); (ii) taking an enzyme-inducing AED: 12 mg/kg/day
target dose (400 mg/d maximum dose); (iii) taking an AED other than valproate plus
an enzyme-inducing AED: 6 mg/kg/d target dose (300 mg/d maximum dose).
Participants over 12 years of age: (i) taking concomitant valproate: 200 mg/d target
dose; (ii) taking an enzyme-inducing AED: 400 mg/d target dose; (iii) taking an AED
other than valproate plus an enzyme-inducing AED: 300 mg/d target dose.
Outcomes
1. % change in primary generalised tonic-clonic seizure frequency monthly
2. % change in other generalised seizure types monthly
3. Median seizure counts monthly
4. Proportion of people with greater than 25% reduction in frequencies of primary
generalised tonic-clonic seizures and all generalised seizures




Trial protocol: GlaxoSmithKline Protocol LAM40097
ClinicalTrials.gov identifier: NCT00043901
Risk of bias




Low risk Quote (from clinical study report): "subjects... were randomised in a 1:1
ratio according to a computer-generated randomization schedule"









Quote (from clinical study report): "...those that meet entry criteria will be
centrally randomised in a 1:1 ratio to receive either lamotrigine or
























Quote: "These data were analyzed for the intent-to-treat population."
Comment: attrition was fully reported and intent-to-treat analysis was
used. However, four randomised participants were excluded from the
analysis because they did not receive at least one dose of study drug. We
were not given the necessary information to incorporate these participants





Low risk Comment: we attained a summary protocol for the study. The results forall predefined outcomes were reported.




Study design: multi-centre, randomised, double-blind, parallel study
Country: North and South America, Europe, and Asia
Study duration:
1. Up to 2-week screening phase
2. 8-week baseline phase
3. 19-week treatment period (7-week double-blind dose-escalation period plus 12-
week double-blind maintenance period)
4. Optional discontinuation or entry into a 52-week continuation phase (7-week
blinded transitional dosing phase plus 45-week maintenance phase)
Participants
Number of randomised participants: 153 (placebo 77 participants; lamotrigine 76
participants)
Number of participants included in efficacy analysis: 143
Type of epilepsy or seizure: confident diagnosis of epilepsy with primary generalised
tonic–clonic seizures
Sex (number (%)): placebo 38/73 (52%) females; lamotrigine 32/70 (46%) females;
Age (mean ± SD): placebo 28.4 ± 11.5 years; lamotrigine 29.4 ± 12.8 years; aged 13
years and over
Number of concomitant AEDs: 1 to 2 AEDs permitted
Interventions
Treatment arms: 1 lamotrigine, 1 placebo
Details: lamotrigine or placebo given as add-on therapy. Participants taking
concomitant valproate: 200 mg/day; participants taking an enzyme-inducing AED with
or without another AED other than valproate: 500 mg/day; participants taking an AED
other than valproate and enzyme-inducing AEDs: 300 mg/day once daily
Outcomes 1. Percentage change in weekly primary generalised tonic–clonic seizure
frequency
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2. 50% or greater reduction in primary generalised tonic–clonic seizure frequency
3. 100% reduction in primary generalised tonic–clonic seizure frequency during
the escalation and maintenance phases combined, during the escalation phase
alone, and during the maintenance phase alone
4. Time taken to 50% reduction in primary generalised tonic–clonic seizure
frequency




Trial protocol: GlaxoSmithKline Protocol LAM100036
ClinicalTrials.gov Identifier: NCT00104416
Risk of bias












Quote (from clinical study report): "Central randomization will be used in
order to ensure that treatment assignment remains balanced. When a
subject has met the criteria for continued study participation at the end of
the baseline phase, the site will call into an IVRS (interactive voice
response system) and that subject will receive the next treatment









Quote (from clinical study report): "After randomization, all subjects will
receive either LTG (lamotrigine) extended-release tablets, or matching

















Quote: "Efficacy data were analyzed using the intent-to-treat population."





Low risk Comment: we obtained a summary protocol for the study. The results forall predefined outcomes were reported.
Other bias Low risk Comment: none detected
[2] AED = Antiepileptic drugs
PGTC = Primary generalised tonic-clonic
Characteristics of excluded studies [ordered by
study ID]
Study Reason for exclusion
Brzakovic
2012
Not a RCT. It was also problematic that all participants were receiving lamotrigine before
enrolment into the study.
Chung
2009 Study only included participants with a diagnosis of focal epilepsy.
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Study Reason for exclusion
Eriksson
1998 Study included participants with Lennox-Gastaut syndrome.
Motte 1997 Study included participants with Lennox-Gastaut syndrome.
Sander
1990
The majority of participants included in the study had focal and secondarily generalised
seizures.
RCT: randomised controlled trial
Appendices
Appendix 1. CRS-web search strategy
1. (epilepax OR lamictal OR lamotrigin*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
2. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
3. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
4. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
5. #2 OR #3 OR #4 AND CENTRAL:TARGET
6. #1 AND #5
7. (monotherap* NOT (adjunct* OR "add-on" OR "add on" OR adjuvant* OR
combination* OR polytherap*)):TI AND CENTRAL:TARGET
8. #6 NOT #7
9. >24/02/2014:CRSCREATED AND CENTRAL:TARGET
10. #8 AND #9
Appendix 2. MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for
identifying randomized trials (Lefebvre 2011).
1. (epilepax OR lamictal OR lamotrigin$).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt.
or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or "add-on" or "add on" or adjuvant$ or combination$
or polytherap$)).ti.
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16. 14 not 15
17. limit 16 to ed=20100601-20190319
18. 16 not (1$ or 2$).ed.
19. 18 and 201$.dt.
20. 17 or 19
21. remove duplicates from 20
Appendix 3. ICTRP search strategy
Condition: epilepsy
Intervention: epilepax OR lamictal OR lamotrigine
Recruitment status: all
Date of registration between 24/02/2014 and 19/03/2019
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SD: standard deviation; SE: standard error; QOLIE-31P: Quality of Life in Epilepsy Inventory-31
Patient-weighted.
Figure 1
Study flow diagram showing the screening results from the searches conducted to March
2019
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Figure 2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as
percentages across all included studies
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Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
Figure 3
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Analysis 1.1
Comparison 1: Lamotrigine versus placebo, Outcome 1: 50% or greater reduction in primary
generalized tonic-clonic seizure frequency







Heterogeneity: Chi² = 0.89, df = 1 (P = 0.35); I² = 0%
Test for overall effect: Z = 4.60 (P < 0.00001)
























M-H, Fixed, 95% CI
1.64 [1.13 , 2.38]
2.11 [1.44 , 3.10]
1.88 [1.43 , 2.45]
Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours placebo Favours lamotrigine
Analysis 1.2






Heterogeneity: Chi² = 0.76, df = 1 (P = 0.38); I² = 0%
Test for overall effect: Z = 1.53 (P = 0.12)
























M-H, Fixed, 95% CI
1.22 [0.57 , 2.60]
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Risk Ratio
M-H, Fixed, 95% CI
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Analysis 1.3






Heterogeneity: Chi² = 0.02, df = 1 (P = 0.88); I² = 0%
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